Cabazitaxel (Jevtana®)

Assessment Status NCPE Assessment process complete
Drug Cabazitaxel
Brand Jevtana®
Indication Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.
Assessment Process
Rapid review commissioned 02/06/2011
Rapid review completed 09/06/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended.
Full submission received from Applicant 03/11/2011
NCPE assessment completed 13/03/2012
NCPE assessment outcome Reimbursement not recommended at the submitted price.

The NCPE believe that, at the submitted price, cabazitaxel is not cost-effective for the treatment of patients with mHRPC previously treated with a docetaxel-containing treatment regimen.

The HSE has approved reimbursement following confidential price negotiations; March 2014.

Technical Summary